Role of nutritional approach in the management of pediatric Crohn's Disease by Sara Geraldes Pacheco Faria Paulino
2016/2017 
Sara Geraldes Pacheco Faria Paulino 
Role of nutritional approach in the management of pediatric Crohn’s Disease/ 
Valor da dieta nutricional na abordagem da Doença de Crohn pediátrica  
março, 2017 
Mestrado Integrado em Medicina 
 
Área: Pediatria 
Tipologia: Monografia 
 
Trabalho efetuado sob a Orientação de: 
Dr. Jorge Manuel Bastos Amil Dias 
 
Trabalho organizado de acordo com as normas da revista: 
Journal of Gastroenterology and Hepatology 
 
Sara Geraldes Pacheco Faria Paulino 
Role of nutritional approach in the management of pediatric Crohn’s Disease/ 
Valor da dieta nutricional na abordagem da Doença de Crohn pediátrica 
março, 2017 


	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Ao meu avô Pacheco 
	  
 
 
 
Role of nutritional approach in the management of pediatric 
Crohn’s Disease 	  	  	  	  	  	  	  	  	  	  	  
Sara Paulino1, Jorge Amil Dias1,2 
 
 
1 Faculdade de Medicina da Universidade do Porto (FMUP), Portugal 
2 Serviço de Pediatria, Centro Hospitalar São João, Porto, Portugal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correspondence 
 
Sara Paulino 
 
Address: Alameda Professor Hernâni Monteiro, 4200-319 Porto, PORTUGAL 
E-mails: mimed11136@med.up.pt  |  sara.geraldes.paulino@gmail.com   
Contact: (+351) 912 919 800 
Fax: (+351) 225 513 601 
	   2	  
ABSTRACT 	  
Crohn’s Disease is a chronic inflammatory condition whose incidence is 
increasing in children worldwide. Nutritional diet is now seen as a way to induce 
remission of pediatric Crohn’s disease (CD) and is considered to be more secure than 
pharmacological therapies. 
The aim of this review is to examine the role of enteral nutrition in the 
induction and/or maintenance of remission in pediatric CD and compare it to 
corticosteroid therapy. Novel diets enriched with omega-3 fatty acids, glutamine and 
transforming growth factor-beta (TGF-β) will also be addressed. 
A search was performed based on Pubmed, Scopus and Web of Science. After 
screening titles, abstracts and some full texts, 44 articles were included. 
Several studies proved that Exclusive Enteral Nutrition (EEN) is as effective 
in inducing clinical and biochemical remission of CD as corticosteroids. However, 
EEN is also capable of healing mucosa, improving height, weight and body mass 
index (BMI). Omega-3 supplemention has not been proven to be beneficial in the 
treatment of CD. Some trials investigated glutamine supplementation, but it was not 
demonstrated its superiority over standard diet. Besides achieving clinical and 
biochemical remission, TGF-β showed efficacy in mucosal healing and decreasing 
pro-inflammatory cytokine levels. Partial Enteral Nutrition (PEN) was not proved to 
be effective in inducing remission, but seems that it can be beneficial in the 
maintenance of remission. 
 Nutritional diet plays a crucial role in the management of pediatric CD, 
however some severe cases need pharmacological therapy which is not discussed in 
this review that concentrated on nutritional intervention. 	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INTRODUCTION 
 
	   Crohn’s disease is a chronic inflammatory condition that can affect any part of 
the gastrointestinal tract. This disease can pop up at any age, mostly in the second 
decade of life. However incidence is increasing in children worldwide and up one 
quarter of the diagnoses are currently made during childhood (1). 
 This disease has a multifactorial etiology, as it depends on genetic, 
immunological and environmental factors. There is reasonable evidence that 
environmental triggers may affect intestinal mucous, microbiome and interaction with 
the mucosa and initiate an exacerbated adaptative immune response in genetically 
susceptible individuals, resulting in inflamation and luminal damage. It has been 
proven that diet is one of these environmental triggers (2-5). 
In pediatric patients, nutritional deficiencies, due to reduced appetite and 
malabsortion, can lead to weight loss, malnutrition, growth failure (about 88% of 
patients), pubertal delay and impairment of disease recovery (1, 6). Furthermore, in 
pediatric-onset, CD tends to be more extensive and complicated compared to adults 
and as the genetic influence may have a more relevant role, leading to earlier clinical 
expression, this may be observed when there are more cases within the family (3, 7). 
 Pharmacological therapy continues to be the main option, including 
corticosteroids, immune modulators, biological agents and antibiotics. However, these 
agents entail relevant side effects, such as increased risk of infection or impairment of 
growth in children (3, 6). 
 Nutrition, besides being a source of energy, promotes linear growth and is 
now also seen as a secure way to induce remission of inflammatory bowel diseases. 
Nutritional diet as a therapy in CD was initiated in the beggining of the 1970’s (8) and 
is currently considered to be the ideal treatment for pediatric patients (9). The 
mechanism of nutritional therapy in pediatric CD is still poorly known but there is 
some evidence that it may be due to bowel rest, modification of the of gut flora, 
enhancement of its barrier function, changes in antigenic stimuli and direct anti-
inflammatory effect of the bowel (1). 
The aim of this review is to examine the role of enteral nutrition in the induction 
and/or maintenance of remission in pediatric CD and compare it to corticosteroid 
therapy. Moreover, some novel diets enriched with anti-inflammatory nutrients such 
as omega-3 fatty acids and glutamine, as well as enriched with cytokines such as 
TGF-β will also be addressed as possible future ways to control the disease. 	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METHODS 	  
 A search was performed, in January 2017, based on the three databases: 
Pubmed, Scopus and Web of Science, using the following keywords (crohn's 
disease)AND(treatment)AND((nutritional diet)OR(polymeric 
diet))AND((pediatric)OR(children)). The search identified 151 articles on Pubmed, 
173 on Scopus and 95 on Web of Science. Duplicated articles were excluded as those 
written in languages other than English. The results were not limited by size, date of 
publication or type of article. After reviewing the titles and abstracts, 75 articles were 
found to be of interest. Of these, those in which full text wasn´t available, were 
excluded. Full texts of the remaining articles were screened and were included those 
that showed relevant dietary evidence, focusing specifically Crohn´s disease. In the 
end, 44 articles were included in the review. 	  	  	  	  
RESULTS 
  
Enteral Nutrition – Induction of remission 
 Enteral nutrition has been a theme of discussion and research since its 
potential role in the treatment of inflammatory bowel diseases, back in the 70’s was 
identified (8). The original diet consisted of elemental diet but subsequently it was 
observed that alternative options might provide some advantages. EEN is now 
considered to be the first line therapy to induce remission in children with active CD 
(7), consisting of a liquid diet as the only source of energy (10). Usually, EEN 
consists of simple components such as protein hydrolizates or amino acids, simple 
carbohydrates, fatty acids and vitamins (3).  
 
Efficacy of EEN in pediatric patients has been proved by several studies (1, 
10-13), resulting in induction of disease remission in a mean of 85% (14). Gavin et al. 
(15) examined data of 40 children newly diagnosed with CD, aged 6-16 years. After 8 
weeks of exclusive feeding with a polymeric diet, all patients showed symptomatic 
improvement and weight gain. In 78%, C-Reactive Protein (CRP) serum levels 
decreased. The location of the affected intestinal segment did not significantly affect 
the results (small bowel, ileocolon and colon). Frivolt et al. (16) also analized health 
records of 52 children treated with EEN. Despite the fact that the majority of patients 
had moderate to severe disease activity, clinical remission rate at week 4 was 71% 
and the improvement rate was 25%. At week 12, remission rate had already been 
achieved by 92% of the children. One of the aims of this investigation was to compare 
results between the first and second courses of EEN. By the fourth week under EEN 
for the second time, 62% of the patients showed remission and 20% showed 
improvement. After one year, remission rate was 77%. Accordingly to this survey, 
EEN efficacy tends to decrease, reaching lower remission rates over the courses and 
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this may be influenced by genetic markers of disease susceptibility, namely NOD2. 
Guidelines of ECCO/ESPGHAN (7) define a standard period of induction therapy of 
6 to 8 weeks and preferably using a polymeric formula rather than an elemental one, 
administered orally. Greater adherence to diet is achieved by oral administration 
comparing to nasogastric tube, that can be especially challenging for children and 
adolescents due to the changes in social dynamic around meals that make them 
frequently feel isolated from their peers. Yet, drinking the formula requires adequate 
motivation from the physician and patient to comply with therapy. Nasogastric tube 
may be used when oral intake is not appropriate and does not ensure delivery of all 
the required energy (10). Regarding type of formula polymeric diets are generally 
preferred due to better taste and lower cost. Elemental feeds should only be given in 
special conditions such as food allergies. Rodrigues et al. (17) evaluated a cohort of 
45 children receiving polymeric formula and 53 receiving elemental formula; 
remission rates weren´t significantly different. Moreover, it was concluded that 
polymeric formula did not alter adherence to EEN, but significantly decreased change 
for nasogastric tube administration. Grogan et al. (18) also observed that rates of 
remission induction of these formulas were similar. However there was a small 
difference in plasma polyunsaturated fatty acids (PUFA) that may be important and 
needs further investigation. Polymeric formula increased eicosapentanoic acid (EPA) 
and alpha linolenic acid (ALA) and decreased arachidonic acid (AA), while elemental 
formula led to increase of EPA and AA and to decrease of docosahexaenoic acid 
(DHA). Another study that compared these two formulas (19) suggested that children 
under polymeric feed gained more weight, although rates of remission were not 
significantly different. As weight recovery is crucial in childhood and adolescence to 
ensure an adequate growth, polymeric formula seems to be superior to elemental. 
 
EEN is capable, not only of inducing clinical and biochemical remission, but 
also to heal bowel mucosa, contrary to corticosteroids which cannot alter submucosal 
inflammatory processes (20, 21). Healing of mucosa influences long-term course of 
CD, representing a great advantage over corticosteroids. Besides correcting nutritional 
deficiencies, EEN positively affects height, weight and BMI, while corticosteroids 
can lead to growth retardation (14). In a prospective study (22), 34 children with a 
mean age of 13 years received EEN for 6 weeks and were followed to evaluate 
disease remission. After nutritional therapy, 84% reached clinical remission with 76% 
achieving both clinical and biochemical remission. Complete mucosal healing was 
obtained in 42% and in 21% there was complete transmural remission of small bowel. 
Berni Canani et al. (21) compared the effects between nutritional therapy and 
corticosteroids in patients with a mean age of 12 years. All of them improved their 
Pediatric Crohn’s Disease Activity Index (PCDAI) scores after 8 weeks, 
independently of treatment. However endoscopic scores showed to be significantly 
better in children treated with diet and only this group achieved histological 
remission. A prospective controlled trial revealed similar results (20) in young 
patients with moderate to severe CD: in the fourth week of the trial, PCDAI, CRP, 
erythrocyte sedimentation rate (ESR) and serum albumin levels decreased equally in 
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both groups treated with polymeric feed and corticosteroids. There was increment in 
height, weight and BMI in both groups, but children under polymeric diet had a 
significantly higher weight gain (weight gain mean of 4.8 kg). Endoscopic and 
histological remission was only observed in polymeric diet group. Anti-inflammatory 
outcomes of polymeric formula were investigated in an in vitro model of epithelial 
cell inflammation, to better understand its mechanisms of action (23) in addition to 
the ability to change gut microflora. After several experiments, it was proposed that 
polymeric therapy has a direct effect on epithelial cells, causing reduction of 
interleukin-8 (IL-8) production. It was also suggested that some component of 
polymeric formulas inhibits phosphorylation of a cellular protein, IκBα, by 
proinflammatory stimuli, preventing NF-κB translocation to nucleus and consequent 
transcription of proinflammatory and immunoregulatory genes. This study confirmed 
a direct anti-inflammatory effect of polymeric diet on enterocytes, limiting production 
and release of chemokines in the presence of proinflammatory stimuli. 
 
In terms of bone health, pediatric Crohn’s disease causes disorganization of 
bone arquitecture, decreases bone mass and increases the risk of fracture (24). This is 
due to malnutrition, vitamin D deficit and use of corticosteroids (1). On the other 
hand, EEN appears to have an anabolic effect on the bone. In a group of newly 
diagnosed patients, an improvement of trabecular bone density and increase in 
cortical bone turnover was observed after treatment with EEN. This diet had already 
been associated with increased biomarkers of bone formation and reduced bone 
resorption in children. Furthermore, there seems to be improvement of muscle mass 
and increment in lean body mass as short-term effects (24). 
 
Whilst induction of remission of CD can be achieved by EEN, maintenance of 
remission using the same strategy is more challenging given loss of adherence over 
time. However, children, treated with EEN for 8 weeks, who achieve remission have 
their risk of relapse decreased. Lambert et al. (25) studied the long-term outcomes of 
nutrition therapy and demonstrated a lower rate of relapse in the group under EEN 
comparing to children taking corticosteroids. Over 24 months of follow-up, 39% of 
patients treated with diet did not relapsed, while in corticosteroids group only 11% 
remianed stable. The mean of relapse episodes in EEN group was 0,5 (range 0-2) and 
1,5 (0-8) in steroid group. Another survey investigated long-term outcome of gut 
microbiome after completion of EEN therapy (26). EEN changed bacterial 
composition of the bowel during the treatment, which may provide an anti-
inflammatory effect. After completion of EEN period and return to normal diet, 
samples from the time of diagnosis and at 4 months post-therapy were compared and 
similarity of 40% in bacteria profile was observed. So, 4 months after nutritional 
induce of remission, intestinal microbiome partially reversed to initial bacteria profile, 
although not completely. The issue of the role of microbiome diversity in the 
pathogenesis and healing of CD is still under intense scrutinity. There is large 
consensus that decreased diversity is associated with higher risk of disease as 
compared to normal controls (27). However there is a paradoxical observation that 
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EEN while improving the disease and promoting mucosal healing also shows to 
induce lower microbiome diversity (28). But despite this paradox, there is some 
evidence that the sequential evaluation of the microbiome modification may predict 
the patients that will evolve into sustained remission after completing the treatment 
with EEN (27). 
 
PEN therapy has also been considered to induce remission. This would mean 
treatment with a nutritional formula that ensures delivery of the majority of the energy 
required combined with limited amount of unristricted diet (10). Johnson et al. (29) 
studied 26 children under PEN and 24 under EEN and verified that remission rate of 
the first one was significantly lower (15% vs. 42% with EEN). Both groups had their 
PCDAI scores significantly diminished, but the decrease in EEN group was greater. 
Relatively to other disease indicators, PEN did not affect levels of haemoglobin, 
platelet count, CRP, ESR and albumin levels. In contrast, EEN showed improvement 
of haemoglobin and albumin levels as well as a significant decrease in platelet count 
and ESR. In conclusion, PEN is not effective in induction of remission of Crohn’s 
disease. 
 
Despite its clear benefit in most cases, regardless of intestinal location of the 
disease, EEN has not shown equal results in perianal disease where other medical and 
surgical options must be considered. 
 
 
Several novel approaches for inducing remission have been examined and 
tested, such as enteral nutrition supplemented with omega-3 fatty acids, glutamine and 
TGF-β. 
 
 
 
 
Omega-3 Fatty Acids 
 It is well established that diet high in fat, especially saturated fats of animal 
origin, has a proinflammatory efect. Regarding polyunsatured fats, omega-6 fatty 
acids (provided by corn oil, safflower seed and cottonseed for example) appear to be 
proinflammatory as well, while omega-3 fatty acids from fish oil or plant-based oils 
have anti-inflammatory activity. According to Lewis et al. (30), diet habits early in 
life may be important in determining predisposition for inflammatory bowel disease 
(IBD). There have been some studies trying to prove this association between early 
dietary patterns and the onset of CD. However it´s difficult to ensure that results are 
strong enough, because data are very heterogeneous and most of the surveys are 
retrospective studies based on dietary histories, hence have low accuracy owing to 
recall bias. 
Nevertheless, some reviews suggest that an increased omega-6/omega-3 ratio 
is associated with higher risk of developing CD (14, 30, 31). A case-control study 
	   8	  
(32) investigated the role of PUFA metabolic genes polymorphisms and dietary 
omega-6/omega-3 fatty acids ratio in the susceptibility of childhood-onset CD. This 
study showed that only children carrying particular CYP4F3 and FADS2 single-
nucleotide polymorphisms have their risk increased. It was then proposed that these 
genotypes favor metabolism of n-6 PUFA and compromise metabolism of n-3, 
resulting in higher levels of proinflammatory mediators, when the fat intake ratio is 
high.  
 
 Although the replacement of n-6 for n-3 fatty acids can reduce the risk of CD, 
it seems that enrichment of enteral feeding with omega-3 fatty acids cannot induce 
remission or avoid the relapse of the disease. In fact, a Cochrane review by Lev-Tzion 
et al. (33) showed that omega-3 supplemention has not been proven to be beneficial in 
the maintenance or induction of remission of CD. On the other hand, a double-blind 
randomized multicenter trial (34) showed advantage in decreasing the amount of total 
fat and omega-6 fatty acids in enteral nutrition, concluding that type of dietary fat 
influences therapy. More investigation is needed to reach a valid conclusion towards 
the role of omega-3 supplementation in therapy of CD, but it is likely that there may 
be relevant influence of the genetic background into these specific benefits of fat 
manipulation. 
 
 
 
 
Glutamine 
Glutamine is a nonessencial amino acid that plays an important role in 
preserving the integrity of intestinal mucosa. In catabolic states, human body may 
demand amounts of glutamine that is unable to synthesize, resulting in glutamine 
deficiency, gut dysfunction and increased permeability (35). As CD leads to catabolic 
metabolism it has been suggested that glutamine may be defficent in active disease 
and that supplementation might be beneficial helping to improve bowel epithelial 
barrier (36). Indeed, there is evidence that children with CD have low plasma 
glutamine (35). However, experimental work did not confirm this benefit and, in fact, 
there may be some proinflammatory effect (31). A double-blind randomized 
controlled trial (36) investigated the effects of glutamine-supplemented enteral diet in 
9 children and compared the results with those of another group of 9 children treated 
with standard diet. After 4 weeks of therapy, there were no significant differences in 
remission rates, platelet count, orosomucoid levels and weight. PCDAI scores of 
patients under standard diet were significantly lower than the scores of the other 
group. Thus, glutamine-enriched diet did not demonstrate superiority over standard 
diet in the treatment of pediatric CD. One possible explanation for this lack of benefit 
might be that glutamine also stimulates T-cells on the intestinal wall, resulting in 
inflammation, or that being a precursor of nitric oxid, it may promote mucosal 
damage.  
 
	   9	  
 
Transforming Growth Factor-Beta  
 TGF-β is a cytokine with a very well recognized role in cell growth, cell 
differentiation and immunoregulation. As it controls differentiation, proliferation and 
activation of some immune system cells – macrophages, lymphocytes and denditric 
cells – TGF-β contributes to anti-inflammatory states and immune tolerance, 
softening autoimmune reactions (31). This effects can be extremely useful in CD 
treatment, making this peptide a potential new supplementation to enteral feeding as 
some studies have been proving. 
  
A study compared fractionated oral vs continuous enteral feeding by 
nasogastric tube in children with moderate to severe disease activity (PCDAI > 30), 
using exclusively a specific oral polymeric diet enriched with TGF-β2 for 8 weeks 
(37). Remission was achieved in 75% of the children of oral group and 85% in the 
enteral group, but also promoted mucosal healing. In fact, all patients with mucosal 
healing showed clinical remission. Fell et al. (38) assessed clinical and endoscopic 
effects as well as mucosal proinflammatory cytokine mRNA in 29 pediatric patients 
treated for 8 weeks with a specific oral polymeric diet enriched with TGF-β2. 
Complete clinical remission was achieved by 79% of children. BMI and weight (mean 
of 3.2 kg) increased. Serum CRP and tumor necrosis factor α levels declined 
significantly. Mucosal macroscopic and histological improvement was observed, 
alongside with down regulation of mucosal proinflammatory cytokines. Thereby, it 
was possible to verify a fall of interferon ϒ mRNA levels in the ileum and a 
decreased level of IL-8 in the colon. Both ileum and colon demonstrated reduced 
levels of interlekin-1β mRNA. Finally, an increase of TGF-β1 mRNA in the ileum 
was found. The decline of these cytokine mRNA expression and concomitant clinical 
remission is consistent with the theory that CD activity is a consequence of an 
inflammatory bowel status (39). Of importance, one year after supplementation with 
TGF-β2, only 39% of the children relapsed, which is considerably lower than the 
relapse rate of enteral nutrition (65%) and corticosteroids (67%). Longer periods of 
administration are needed to appropriately evaluate efficiency of this protein in 
maintenance of remission (38). Hartman et al. (40) analized and compared disease 
activity of 28 Israeli children receiving TGF-β enriched formula to 18 children treated 
with standard polymeric formula and 18 children without supplementation. A 
significant decrease in PCDAI was noticed in the first two groups (from 34.3 to 15.7 
and 35.0 to 22.0, respectively). No improvement was seen in the third group. Besides, 
only children receiving TGF-β registered significant improvements in ESR and BMI, 
which suggests a benefit of  this type of formula in the treatment of pediatric patients 
with growth retardation. 
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Enteral Nutrition – Maintenance of remission 
The use of EEN has gathered wide acceptance in the treatment of active CD in 
pediatric patients, although relapse occurs in a considerable number of patients in the 
following months (16). Maintenance of remission is therefore an important aspect of 
long-term treatment. To maintain remission for a longer period, various strategies 
have been evaluated involving nutritional manipulation. The use of PEN has also been 
considered in this context. A prospective study was conducted (6) to analize the effect 
of short-term suportive partial enteral nutrition (SPEN) in children with severe 
activity of disease. After one year of treatment, nutritional status indicators assessed 
by weight, height, hemoglobin, transferrin saturation, ferritin, albumin, some 
electrolytes and vitamins, changed siginificantly with SPEN. This improvement of 
nutritional status was more evident in the SPEN group constituted by younger patients 
(<13 years). Decrease of PCDAI score was also significantly higher in SPEN group 
than in non-SPEN one. This study has proved that SPEN as a secondary treatment 
along with conventional medical treatment is effective in improvement of nutritional 
status and in attenuating disease severity in children, especially in younger patients. 
Thereby, PEN is not effective in inducing remission, but it can be beneficial as a 
supportive therapy for maintenance of remission of pediatric CD. Clearly, the benefit 
of this approach requires long term motivation of the patient and family. 
 
 
Another emerging type of therapy for maintenance of remisson that has been 
explored is exclusion diet. 
 
 
 
 
Specific Carbohydrate Diet 
Exclusion diets including selected and restricted ingredients, despite being 
very rigorous, if effective, may facilitate adherence by pediatric patients (11). Specific 
Carbohydrate Diet (SCD) is an attractive example of exclusion diet that may allow 
children to have a more normal life. This intervention removes refined sugars and 
restricts complex carbohydrates, since undigested and malabsorved carbohydrates 
lead to fermentation in the bowel, bacterial overgrowth and change fecal microbiome 
to a proinflammatory state (41). SCD restricts the intake of grains and starches such 
as wheat, rice, corn or potatoes. Alternatively, patients can eat baked food or breads 
made with nut, almond or coconut flours. Almost all milk products are eliminated, 
except for lactose free natural cheeses or fully fermented yogurt. Processed foods are 
prohibited and the only acceptable added sugar is honey. Recently, this dietary 
approach has been attracting interest as having therapeutic potential in IBD (42, 43). 
Several studies have demonstrated the efficacy of SCD in CD (2). Cohen et al. (43) 
examined clinical improvement, based on PCDAI, and mucosal healing in pediatric 
patients with active CD with a mean age of 13.6 years. After 12 weeks of SCD, 60% 
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of the patients showed clinical remission and 80% showed significant mucosal 
improvement, with 40% achieving mucosal healing. Suskind et al. (42) investigated 
medical records of routine clinic visits of 10 patients,  aged between 7 and 16 years, 
within a regimen of SCD for 5-30 months. Laboratory parameters and fecal 
calprotectin significantly improved and in some patients even came to normal values. 
Regarding symptoms, after three months of treatment all of the patients had their 
symptoms solved. Seattle Children’s Hospital IBD Center developed an integrated 
dietary program using SCD as primay therapy for IBD or as adjunctive therapy when 
there is partial response to medication (44). Medical records of a group of patients 
under SCD protocol were reviewed. Then, clinical and laboratory outcomes of this 
group and a control one were compared in certain periods of time (before diet, 2-6 
week, 4-6 month, 7-11 month and in the 12th month of diet). There was an overal 
benefit in the disease activity but also some variation in the dietary protocol as well as 
weight loss in some cases due to inadequate compliance. This study suggests that 
there may be a role for dietary manipulation in the context of medical treatment but 
still insufficient to provide specific clinical guidance. 
 
In terms of liberalization, Burgis et al. (41) performed a retrospective chart 
review of patients with CD treated with SCD. Patients were divided into two groups: 
one group included children treated with SCD alone or in combination with only 
antibiotics or 5-ASA, and the second group embraced children within SCD in 
combination with immunomodulators. After following a strict SCD, patients 
liberalized their own diet adding an illegal ingredient daily or adding illegal meals at 
varying frequency, sometimes daily as well. Hematocrit levels improved when 
children initiated strict SCD and remained stable with liberalization, in both groups. 
Albumin levels also significantly improved with strict diet, but a greater difference 
was noticed on SCD with immunomodulator group (0,9 g/dL vs 0.6 g/dL; P-value < 
0.001). During liberalization time, albumin levels droped a little in this same group. 
There was significant decrease of  ESR with strict diet that continued relatively stable 
with liberalized diet, without significant differences between groups. While on strict 
diet, most of the children improved weight (90%) and height (82%) percentiles. 
During liberalization period, it was observed just a small mean decline in weight (less 
than 1 percentile) and an increase in height percentile, resulting in a relatively stable 
growth. Therefore, it seems to be possible to adopt a less strict carbohydrate diet, 
carefully adding some ingredients and foods, and still remain in remission of CD.  
 
 
However, the wide use of these approaches, especially if used without 
concomitant pharmacologic therapy requires careful previous validation. Dietary 
restrictions may induce nutritional deficiencies and indeed some of the patients have 
lost weight in some of the published studies. Furthermore, most cases of active 
pediatric CD occur in adolescents which is a delicate time for the growth spurt. 
Interference in this unique window for growth may limit the achievement of 
individual genetic potential. While it is desirable that research may provide clear 
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answers and recommendations regarding the use of nutrition as long-term tool to 
control CD, there must be great caution to avoid hasty advise that may turn to be 
deleterious in the long run. 
 
 
 
 
CONCLUSION 
 EEN has shown to be the best option to induce remission in most cases of 
pediatric CD, leading to clinical, endoscopic and histological improvement, while 
correcting nutritional deficits ensuring linear growth of children. Due to similar 
efficacy, this nutritional approach compares favourably with corticosteroids, that bear 
some relevant side effects in children. Regarding supplemented diets, the role of 
enrichment with omega-3 fatty acids and glutamine is not conclusive, needing more 
investigation. TGF-β appears to be effective, leading to improvement of disease 
activity; therefore, it may enhance the overall benefit of EEN to induce remission. It 
is important to keep in mind that some cases with deep colonic ulceration, severe 
growth retardation and perianal disease may benefit from other concomitant or 
alternative pharmacological options that were beyond the scope of this review that 
concentrated on nutritional intervention. For maintenance of remission, PEN seems to 
be beneficial as a supportive therapy. Specific elimination diets, may prove to be of 
great benefit and clinical importance, as they may sustain clinical remission and 
mucosal healing while receiving improved compliance for long term treatment in 
pediatric patients and lead to some sparing of drug treatment. 
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